An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2011 Sep 8

PMID 21898493

Citations 379

Authors

Marc G Ghany

David R Nelson

Doris B Strader

David L Thomas

Leonard B Seeff

Affiliations

Soon will be listed here.

Citing Articles

Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV/HIV Coinfection in a Real Life Setting.

Roman Lopez C, Triana Gonzalez S, Cano Diaz A, Lopez D, Mata Marin J, Gaytan Martinez J Viruses. 2024; 16(11).

PMID: 39599839 PMC: 11599026. DOI: 10.3390/v16111724.

Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.

Kamal S, Shahzad A, Rehman K, Tariq K, Akash M, Imran M Curr Med Chem. 2023; 31(15):2052-2072.

PMID: 37855348 DOI: 10.2174/0109298673234823230921090431.

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.

Izhari M Diagnostics (Basel). 2023; 13(19).

PMID: 37835845 PMC: 10572573. DOI: 10.3390/diagnostics13193102.

Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD.

Coyle C, Desjardins M, Curriero F, Rudolph J, Astemborski J, Falade-Nwulia O J Viral Hepat. 2023; 30(10):810-818.

PMID: 37382024 PMC: 10527489. DOI: 10.1111/jvh.13864.

Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.

Shaikh A, Goli K, Lee T, Rich N, Benhammou J, Keeling S Clin Gastroenterol Hepatol. 2022; 21(9):2288-2297.e4.

PMID: 36521738 PMC: 10686256. DOI: 10.1016/j.cgh.2022.11.038.

References

Mangia A, Thompson A, Santoro R, Piazzolla V, Tillmann H, Patel K . An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010; 139(3):821-7, 827.e1. DOI: 10.1053/j.gastro.2010.05.079. View

Sarrazin C, Kieffer T, Bartels D, Hanzelka B, Muh U, Welker M . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132(5):1767-77. DOI: 10.1053/j.gastro.2007.02.037. View

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H . Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52(2):421-9. DOI: 10.1002/hep.23690. View

Silva M, Treitel M, Graham D, Curry S, Frontera M, McMonagle P . Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol. 2013; 59(1):31-7. DOI: 10.1016/j.jhep.2013.02.018. View

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View

Veldt B, Heathcote E, Wedemeyer H, Reichen J, Hofmann W, Zeuzem S . Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007; 147(10):677-84. DOI: 10.7326/0003-4819-147-10-200711200-00003. View

Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T . Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360(18):1839-50. DOI: 10.1056/NEJMoa0807650. View

McHutchison J, Everson G, Gordon S, Jacobson I, Sulkowski M, Kauffman R . Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360(18):1827-38. DOI: 10.1056/NEJMoa0806104. View

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S . Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25):2417-28. DOI: 10.1056/NEJMoa1013086. View

10.

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

11.

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

12.

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

13.

Thompson A, Muir A, Sulkowski M, Ge D, Fellay J, Shianna K . Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139(1):120-9.e18. DOI: 10.1053/j.gastro.2010.04.013. View

14.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. DOI: 10.1038/ng.449. View

15.

. American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology. 1995; 108(3):925-6. DOI: 10.1016/0016-5085(95)90469-7. View

16.

Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. DOI: 10.1038/nature08309. View

17.

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

18.

Morgan T, Ghany M, Kim H, Snow K, Shiffman M, De Santo J . Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010; 52(3):833-44. PMC: 2932862. DOI: 10.1002/hep.23744. View

19.

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View

20.

Bacon B, Gordon S, Lawitz E, Marcellin P, Vierling J, Zeuzem S . Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1207-17. PMC: 3153125. DOI: 10.1056/NEJMoa1009482. View